272 related articles for article (PubMed ID: 38444031)
21. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
22. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
23. State of the art in CAR T cell therapy for CD19+ B cell malignancies.
Frigault MJ; Maus MV
J Clin Invest; 2020 Apr; 130(4):1586-1594. PubMed ID: 32235098
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M; Korell F; Porazzi P; Maus MV
Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
[TBL] [Abstract][Full Text] [Related]
25. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
26. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
27. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.
Moreno-Castaño AB; Fernández S; Ventosa H; Palomo M; Martinez-Sanchez J; Ramos A; Ortiz-Maldonado V; Delgado J; Fernández de Larrea C; Urbano-Ispizua A; Penack O; Nicolás JM; Téllez A; Escolar G; Carreras E; Fernández-Avilés F; Castro P; Diaz-Ricart M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37045474
[TBL] [Abstract][Full Text] [Related]
29. Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
Mumtaz AA; Fischer A; Lutfi F; Matsumoto LR; Atanackovic D; Kolanci ET; Hankey KG; Hardy NM; Yared JA; Kocoglu MH; Rapoport AP; Dahiya S; Li AS; Sunshine SB
Br J Ophthalmol; 2023 Jul; 107(7):901-905. PubMed ID: 35144919
[TBL] [Abstract][Full Text] [Related]
30. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
31. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
[TBL] [Abstract][Full Text] [Related]
32. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
33. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
Kim SJ; Yoon SE; Kim WS
Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
[TBL] [Abstract][Full Text] [Related]
34. [Indications for CAR-T cell therapy and management of the complications: an update].
Di Lorenzo S; Errichiello S; Cerne D; Venturini M; Visintini C
Assist Inferm Ric; 2022; 41(4):195-211. PubMed ID: 37283174
[TBL] [Abstract][Full Text] [Related]
35. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
36. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
37. Toxicities associated with adoptive cellular therapies.
Hansen DK; Dam M; Faramand RG
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
[TBL] [Abstract][Full Text] [Related]
38. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
40. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]